Overview
BLTE market data
Price History
BLTE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.31 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.19 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $60.00 – $200.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $6.3K · P/B 7.28.
Company news
Why Is Belite Bio Stock Gaining Monday?Benzinga · Jul 20, 2026, 5:35 PM
Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In MontréalBenzinga · Jul 20, 2026, 12:06 PM
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor SymposiumGlobenewswire Inc · Jul 6, 2026, 12:15 PM
HC Wainwright & Co. Reiterates Buy on Belite Bio, Maintains $200 Price TargetBenzinga · Jun 15, 2026, 11:55 AM
Full Transcript: Belite Bio Q1 2026 Earnings CallBenzinga · Jun 1, 2026, 1:08 PM
Mizuho Maintains Outperform on Belite Bio, Lowers Price Target to $215Benzinga · May 26, 2026, 5:25 PM
Earnings Scheduled For May 20, 2026Benzinga · May 20, 2026, 11:15 AM
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate UpdateGlobenewswire Inc · May 20, 2026, 11:15 AM
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in SwitzerlandGlobenewswire Inc · May 18, 2026, 8:15 PM
Belite Bio's Tinlarebant Receives Orphan Drug Status From Swiss Agency For Therapeutic Products To Treat Stargardt DiseaseBenzinga · May 18, 2026, 8:05 PM